drugset / Trial / NCT00268710
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objectives: * To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: * To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as second line therapy in HRPC * To evaluate PSA response (PSA: Prostate Specific Antigen) * To evaluate symptomatic response * To evaluate Quality of life * To evaluate patient safety of weekly versus q3 weekly regimens of Taxotere®.
Timeline
- Start
- 2004-02
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |